ArticleEuropean journal of immunology2026
Sialylation in Colorectal Cancer Rewires Antitumor Immunity at the Peritoneal Metastatic Site.
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Colorectal cancer (CRC) patients are frequently diagnosed with metastases to the peritoneal cavity. These patients have a dismal prognosis and only limited therapeutical benefits. Solid tumors, including CRC, often display elevated levels of sialylated glycan structures, acting as immune checkpoints for immune evasion. However, the detrimental effects of tumor sialylation on antitumor immunity at the peritoneal site remain unexplored. We uncovered that sialylation is higher in peritoneal metastases (PM) compared with primary CRC or liver metastases. Intraperitoneal injection of sialic acid-deficient CT26 CRC cells led to significantly less peritoneal tumor development and a lower peritoneal cancer index (PCI) score. Sialic acid-devoid tumors harbored higher numbers of live CD45
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.